chrisvoncsefalvay/vaers-outcomes huggingface dataset:
weakness; tiredness; his knees, which were normally in a "constant state of pain", started "flaring up; his knees, which were normally in a "constant state of pain", started "flaring up; injection site also "flared up"; arm soreness; This is a spontaneous report from a contactable consumer, the patient. A 25-year-old male patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Formulation: Solution for injection, Lot Number: UNKNOWN), via an unspecified route of administration on an unspecified date as single dose for COVID-19 immunisation. Medical history included constant state of knee pain. The patient's concomitant medications were not reported. It was reported that the caller was a 25-year-old male who received his Pfizer BioNTech COVID-19 vaccine at about 11:00AM on Monday and by Tuesday around 4:00-5:00, he started experiencing side effects that he would like to know if they were related to the vaccine. Caller stated that he was "struck with a feeling of weakness and tiredness" like he was sick. He also reported that his knees, which were normally in a "constant state of pain", started "flaring up." He also reported that the injection site also flared up around the same time. Caller stated that now his knees were back to normal, he does not feel fatigued, and that his arm soreness was "mostly gone." He was just unsure if these side effects could be related to the vaccine as they occurred "28 to 29 hours" after he received his dose. It was unknown if the patient received the treatment for the events. Outcome of the event fatigue, his knees which were normally in a constant state of pain started flaring up were recovered on an unspecified date, arm soreness was recovering and unknown for other events.  Information on the lot/batch number has been requested.
elevated heart rate pounding heart beat (could hear it) Pounding headache Turned red like a cherry warm
Patient reported lightheadedness and feeling nauseas and faint about 2 minutes after vaccination. Placed supine for about 5 minutes with good effect. Water provided. Reported she did not eat breakfast this morning. Patient was in recovery for  30 minutes. Patient reported feeling well.  Advised patient to complete VAERS side effect report.  Picked up by boyfriend at 10:40.  Advised patient to eat before next vaccine visit. Advised patient to lay down  at next vaccine appointment. Patient stable at discharge.
Rash like hives, right eye shut , lips swollen; Rash like hives, right eye shut , lips swollen; Rash under left arm; Swelling of lymph nodes in both armpits; Rash hot to touch; Headache; Flu like symptoms; Rash behind Knee, size of golf ball and bumpy,Rash pretty bad on stomach and back,rash first on upper part of body extending lower part of body.; Tired feeling; Itching and soreness all over body; Itching and soreness all over body; This spontaneous case was reported by a consumer and describes the occurrence of RASH (Rash behind Knee, size of golf ball and bumpy,Rash pretty bad on stomach and back,rash first on upper part of body extending lower part of body.), FATIGUE (Tired feeling), PRURITUS (Itching and soreness all over body), PAIN (Itching and soreness all over body) and URTICARIA (Rash like hives, right eye shut , lips swollen) in a 29-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 044A21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    On 22-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 22-Mar-2021, the patient experienced RASH (Rash behind Knee, size of golf ball and bumpy,Rash pretty bad on stomach and back,rash first on upper part of body extending lower part of body.), FATIGUE (Tired feeling), PRURITUS (Itching and soreness all over body) and PAIN (Itching and soreness all over body). On 28-Mar-2021, the patient experienced URTICARIA (Rash like hives, right eye shut , lips swollen), DYSKINESIA (Rash like hives, right eye shut , lips swollen), RASH (Rash under left arm), LYMPHADENOPATHY (Swelling of lymph nodes in both armpits), VACCINATION SITE WARMTH (Rash hot to touch), HEADACHE (Headache) and INFLUENZA LIKE ILLNESS (Flu like symptoms). At the time of the report, RASH (Rash behind Knee, size of golf ball and bumpy,Rash pretty bad on stomach and back,rash first on upper part of body extending lower part of body.) and RASH (Rash under left arm) was resolving and FATIGUE (Tired feeling), PRURITUS (Itching and soreness all over body), PAIN (Itching and soreness all over body), URTICARIA (Rash like hives, right eye shut , lips swollen), DYSKINESIA (Rash like hives, right eye shut , lips swollen), LYMPHADENOPATHY (Swelling of lymph nodes in both armpits), VACCINATION SITE WARMTH (Rash hot to touch), HEADACHE (Headache) and INFLUENZA LIKE ILLNESS (Flu like symptoms) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medication information was provided by the reporter.  The patient's treatment medications included: Zyrtec, Benadryl ,Prednisone, and Tylenol.  Upon internal review on 04-AUG-2021, the age was corrected to 29 years.
Doses administered after more than 1 temperature excursion; Doses administered after more than 1 temperature excursion; This spontaneous case was reported by an other health care professional and describes the occurrence of PRODUCT TEMPERATURE EXCURSION ISSUE (Doses administered after more than 1 temperature excursion) and POOR QUALITY PRODUCT ADMINISTERED (Doses administered after more than 1 temperature excursion) in a 72-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 019B21A and 014M20A) for COVID-19 vaccination.     No Medical History information was reported.   On 28-Feb-2021 at 11:30 AM, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .5 milliliter. On 28-Mar-2021 at 11:42 AM, received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to .5 milliliter. On 28-Mar-2021 at 11:42 AM, the patient experienced POOR QUALITY PRODUCT ADMINISTERED (Doses administered after more than 1 temperature excursion). On an unknown date, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (Doses administered after more than 1 temperature excursion). At the time of the report, PRODUCT TEMPERATURE EXCURSION ISSUE (Doses administered after more than 1 temperature excursion) and POOR QUALITY PRODUCT ADMINISTERED (Doses administered after more than 1 temperature excursion) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Age was reported as 72.63 on 28-Feb-2021 and 72.71 on 28-Mar-2021    No concomitant product reported by reporter. The reported condition of the vial was not frozen. Vaccine was moved to fridge on 23-Mar-2021, Vaccine was moved to clinic on 27-Mar-2021.Number of vials sent to clinic were 15 and Total doses given for the day were 150 Vaccine underwent temperature excursion on 28-Mar-2021 till 35 degrees Fahrenheit at 10 AM and Best Use Date for the vaccine was 22-Apr-2021. It was reported that unknown number of patients were administered with vaccines that experienced more than 1 temperature excursion during 33 weeks on 2021. The HCP explained that each time a vial was put into a cooler, there was a period of time of 1 hour or 1 hour and a half approximately, when the temperature data logger registered 34 or 35 degree F. Vial was punctured right before administration. No treatment medication reported by reporter.
The patient became pale with blurred vision. The patient remained alert and oriented. The patient's blood pressure had dropped and he began having ringing in his ears.  The patient was assisted to the medical cot and given some water. The patient's color improved, his vision improved and the ringing subsided. The patient's vitals were continuously monitored for the 9 minutes it took him to fully recover and his vitals to return to normal. We continued to monitor the patient for an additional 15 minutes without complication or further change.
My heart just perked-chest pains-closer to the center of my heart, heart rate was increasing, and shortness of breath. These symptoms lasted  for a week of 2.
Hives began several days after the first vaccination.  Over the counter antihistamines were used for treatment.  The hives got a little better after 10 days, but never went away. Once I received the second shot, the hives immediately spread and became worse.  Oral steroids, pepcid, zyrtec and claritin were prescribed as treatment.
Bleeding gums , painless bruises of back,  Started about 10 days after vaccine, has now 02/16/21 stopped
knot at the injection site; Warm to the touch knot at the injection site; Tenderness at the injection site; right upper lip edema; This spontaneous case was reported by a consumer and describes the occurrence of LIP OEDEMA (right upper lip edema), VACCINATION SITE NODULE (knot at the injection site), VACCINATION SITE WARMTH (Warm to the touch knot at the injection site) and VACCINATION SITE PAIN (Tenderness at the injection site) in a 74-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 013M20A) for COVID-19 vaccination.     No Medical History information was reported.    On 04-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 04-Feb-2021, the patient experienced LIP OEDEMA (right upper lip edema). On 05-Feb-2021, the patient experienced VACCINATION SITE NODULE (knot at the injection site), VACCINATION SITE WARMTH (Warm to the touch knot at the injection site) and VACCINATION SITE PAIN (Tenderness at the injection site). At the time of the report, LIP OEDEMA (right upper lip edema), VACCINATION SITE NODULE (knot at the injection site), VACCINATION SITE WARMTH (Warm to the touch knot at the injection site) and VACCINATION SITE PAIN (Tenderness at the injection site) had resolved. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No treatment information was provided.  No concomitant medication was provided.
Temperature excursion that was intermittent invoving VARIVAX states that there have been administered doses; This spontaneous report was received from a registered nurse referring to a patient of unknown age and gender.  No information regarding the patient's pertinent medical history, drug reactions or allergies and concomitant therapies was provided.  On an unknown date in 2020, the patient was vaccinated with an improperly stored dose of varicella virus vaccine live (oka/merck) (VARIVAX) lot number S032357, expiration date 14-OCT-2021, and lot number T002843, expiration date 23-JAN-2022, 0.5 milliliter for prophylaxis (route of administration, vaccination scheme frequency, and anatomical location were not reported). The administered dose of the vaccine experienced a temperature excursion that was intermittent beginning on 28-JUL-2020 (onset date also reported as 12-AUG-20202) of -14 degrees Celsius to -10 degrees Celsius (max -9.5 C) for a total of 38 hours and 30 minutes, as recorded by a data logger.  This is one of several reports received from the same reporter.; Sender's Comments:  US-009507513-2008USA014701: US-009507513-2008USA014711: US-009507513-2008USA014788:
NO TREATMENT DONE CURRENTLY, WILL ISOLATE UNTIL CRUSTED OVER, RED SPOTS OF TRUNK, ARMS, AND FACE WITH SOME CRUSTED OVER.
itchy arm; inflamed arm; red arm; This spontaneous case was reported by a consumer and describes the occurrence of INJECTION SITE PRURITUS (itchy arm), VACCINATION SITE INFLAMMATION (inflamed arm) and VACCINATION SITE ERYTHEMA (red arm) in a 40-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 029L20A) for COVID-19 vaccination.     No Medical History was provided by the reporter.    On 21-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form.   On 28-Jan-2021, the patient experienced INJECTION SITE PRURITUS (itchy arm), VACCINATION SITE INFLAMMATION (inflamed arm) and VACCINATION SITE ERYTHEMA (red arm). The patient was treated with DIPHENHYDRAMINE HYDROCHLORIDE (BENADRYL [DIPHENHYDRAMINE HYDROCHLORIDE]) for Adverse event, at an unspecified dose and frequency and ACETAMINOPHEN for Adverse event, at an unspecified dose and frequency.   At the time of the report, INJECTION SITE PRURITUS (itchy arm), VACCINATION SITE INFLAMMATION (inflamed arm) and VACCINATION SITE ERYTHEMA (red arm) outcome was unknown. Not Provided    The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   Concomitant product use was not provided by the reporter.
Left arms swelled up and has itched on and off the last few days . On day 2 had aching and flu like symptoms
Rash; Sweating; Vomiting; high fever; arm is still hurting her; Dizziness; This is a spontaneous report from a contactable consumer or other non hcp (patient). A 53-year-old female patient received first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 MRNA VACCINE, formulation: solution for injection, #lot number: EW0171) via an unspecified route of administration, administered in right arm on 22Apr2021 13:55 as single dose for covid-19 immunisation. The patient received second dose of bnt162b2 (PFIZER-BIONTECH COVID-19 MRNA VACCINE, formulation: solution for injection, #lot number: EW0176) via an unspecified route of administration, administered in her left arm on 13May2021 15:00 as single dose for covid-19 immunisation. The patient's medical history and concomitant medications were not reported. On 23Apr2021, the patient experienced dizziness and the day after she got the first shot was when her arm started killing her and also stated it has improved but if she pushes on her arm it still hurts. On 24Apr2021, patient experienced vomiting and high fever. On 26Apr2021, patient experienced sweating and on 28Apr2021 patient developed rash. Patient confirmed that confirmed that the symptoms started after she received the COVID 19 vaccine. The patient underwent lab test which included body temperature: 101 Fahrenheit. Therapeutic measures were taken as a result of events dizziness, rash, sweating, vomiting, high fever, arm is still hurting her. Treatment drugs included Mucinex and Tylenol. Patient stated sweating stopped last week around 01May2021 but then she got her second shot and it started back up again and is still going on. The outcome of the event dizziness, sweating and rash was not recovered and the outcome of the event high fever and vomiting was recovered on 30Apr2021 and the outcome of the event arm is still hurting her was recovering.  Follow-up attempts are completed. No further information is expected.
patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion); patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion); This spontaneous case was reported by an other health care professional and describes the occurrence of PRODUCT TEMPERATURE EXCURSION ISSUE (patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)) and POOR QUALITY PRODUCT ADMINISTERED (patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)) in a 52-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .25 milliliter. On an unknown date, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)) and POOR QUALITY PRODUCT ADMINISTERED (patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)). At the time of the report, PRODUCT TEMPERATURE EXCURSION ISSUE (patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)) and POOR QUALITY PRODUCT ADMINISTERED (patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications were reported.  The reporter stated that, their facility had not been able to download the digital data logger, they had been put on hold by the state at the moment. There had been no power outages that would have impacted the Moderna vaccine.  It was reported that, the facility was unable to download the digital data logger, they would need to treat this issue as a temperature excursion. The data logger was unable to download for the months of Dec-2021, Jan-2022, and Feb-2022. The reporter did not have any questions and wanted to report this to Moderna.  The reporter stated that no adverse reactions were reported by any patients.  No treatment medications were reported.
I got the FLUVIRIN shot and in 1 hr. arm swelled 2x size - turned red - itched terrible - whole arm and shoulder had bone pain - fever 101.9 - bicept briusing hand size was unable to use my left arm for 5 days it has been 10 days and my shoulder is still sore-like a deep bone pain. I can use my arm now - but is still bruised.
Pt states that he still feels muscle soreness from the shot since 10/31/2014. Pt will get tested on 12/29/14. He is unsure if he pulled a muscle, or it is from the shot.
This spontaneous report was received from a physician via a company representative and refers to a patient of unknown age and gender. The patient's concurrent conditions and medical history were not reported. On 11-NOV-2015, the patient was vaccinated with a dose of improperly stored VAQTA (10Pk 50U/1 mL) lot number K008984, expiration date of 21-OCT-2015 (route of administration was not reported), which was stored 6 times with the following lowest recorded temperatures: 34F (1.111 celsius degrees) for 88 hours, 29F (-1.666 celsius degrees) for 184 hours and 30F (-1.111 celsius degrees) for 152 hours, 31F (-0.555 celsius degrees) for 344 hours, 32F (0 celsius degrees) for 264 hours and 33 F (0.555 celsius degrees) for 152 hours. No highest reported temperatures were reported. The type of storage was refrigerator. No concomitant therapies were reported. No adverse effects were reported. No product quality complaint (PQC) was involved. This is one of several cases from the same reporter. Additional information has been requested.
Swollen lymph node above left clavicle the size of avocado, pain and tenderness in neck and left shoulder.
Systemic: Fainting / Unresponsive-Mild, Systemic: Nausea-Mild, Systemic: Vomiting-Mild, Additional Details: Patient fainted 5-7 minutes after receiving the vaccine. She regain consciousness within 3 minutes before the paramedic arrived. Patient felt nauseous and vomitted. Her vitals were checked and they come out normal. Patient stated she was nervous and did not drink water and only had a bagel before getting her vaccine.
rapid heart beats; This is a spontaneous report from a contactable consumer (Patient). A female patient of an unspecified age received bnt162b2 (BNT162B2, PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, Batch/Lot number was not reported), via an unspecified route of administration on 15Jul2021 as DOSE NUMBER UNKNOWN, SINGLE for covid-19 immunisation. The patient medical history and concomitant medications were not reported. stated she got the shot on 15Jul2021 and she has been having rapid heartbeats. On Jul2021, The patient experienced rapid heartbeats. The patient underwent lab tests and procedures which included heart rate: rapid heartbeats on Jul2021. The outcome of the events was unknown.  Information on the lot/batch number has been requested.
7JUL came to ER w/temp cranky dx local rxn to vax w/early inflammation lt femur;
Patient was given COVID vaccine, 1st dose. About 5 min later patient said he felt weird and was nauseous, was walking around agitated and said he threw up once. Also complained of chest pain. Denied SOB, trouble breathing. Pt went to ER to be evaluated. Tested for COVID and found to be positive.
Two hours post vax, the pt developed a fever. This is 2 of 2 pts from this facility who experienced fever following receipt of vax.
Shoulder pain, progressed after three weeks to extreme shoulder pain at night, limitation of range of motion. Pain and limitation of range of motion still present after two months (and continuing).
Soreness; Time  between the first dose and the second is about 62 days; This spontaneous case was reported by a consumer and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Time  between the first dose and the second is about 62 days) and MYALGIA (Soreness) in a 36-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 027B21A) for COVID-19 vaccination.     No Medical History information was reported.    On 03-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 03-Apr-2021, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Time  between the first dose and the second is about 62 days). On an unknown date, the patient experienced MYALGIA (Soreness). On 03-Apr-2021, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Time  between the first dose and the second is about 62 days) had resolved. At the time of the report, MYALGIA (Soreness) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medication details was reported. No treatment medication details was reported.   This case was linked to MOD-2021-270267 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 28-Jul-2021: Significant follow-up: Event added
soreness in the arm; woozy; headache; This is a spontaneous report from a contactable consumer. This 74-year-old male consumer reported that he received first and second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, formulation: Solution for injection, Lot Number: Unknown, and Expiration date: Unknown), via an unspecified route of administration on an unspecified date as single dose for COVID-19 immunization. The patient medical history and concomitant medications were not reported. It was reported that the patient received both doses of Pfizer's COVID vaccine and had soreness in the arm. The first night, he felt kind of woozy and as the day went on, he got better. He took some Tylenol and started feeling better every day. The patient stated he experienced a headache a couple days ago, but it was nothing serious. The outcome of the event woozy was reported as recovering. The outcome of events soreness in the arm and headache was unknown.  Follow-up attempts are completed. No further information is expected.
Patient states that she had multiple blood clots in lungs and legs and was hospitalized. She said that the hospital staff was unable to state definitely that it was due to the vaccine but they felt that it was likely. Patient states she was put on Eliquis and is now on warfarin, most likely forever.
Headache, Myalgia, Arthralgia, Diarrhea, Fatigue Narrative:
MYOCARDITIS 3/9/2022 OSTEOPOROSIS MYOCARDITIS 3/9/2022 SYSTOLIC HEART FAILURE, ACUTE MYOCARDITIS 3/9/2022 SLE (SYSTEMIC LUPUS ERYTHEMATOSUS)